Haemonetics (($HAE)) has held its Q3 earnings call. Read on for the main highlights of the call. The latest earnings call from Haemonetics ...

Haemonetics’ HAE major growth drivers include Plasma and the Hospital business. However, rising costs are a concern. The stock carries a Zacks Rank #3 (Hold) currently.

Haemonetics demonstrated robust growth in its hospital business, led by innovations in hemostasis management and vascular closure. While plasma revenue faced headwinds from CSL's transition ...

StockNews.com upgraded shares of Haemonetics (NYSE:HAE – Free Report) from a hold rating to a buy rating in a report published on Friday. HAE has been the topic of a number of other reports. Bank of ...

Mizuho lowered the firm’s price target on Haemonetics (HAE) to $90 from $115 and keeps an Outperform rating on the shares post the earnings ...

JMP Securities lowered the firm’s price target on Haemonetics (HAE) to $100 from $125 and keeps an Outperform rating on the shares. Haemonetics ...

Haemonetics Corporation’s HAE growth in the fiscal second quarter of 2025 can be attributed to the strong potential of the Plasma franchise. The robust uptake of the NexSys PCS system bodes well ...

Haemonetics Corp (NYSE:HAE) is gaining market share in the plasma segment, particularly in the US and Europe, through technology upgrades and new long-term agreements with BioLife and Grifols.